M
Maria Luisa Veronese
Researcher at Hoffmann-La Roche
Publications - 6
Citations - 1477
Maria Luisa Veronese is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Vemurafenib & Cancer. The author has an hindex of 4, co-authored 6 publications receiving 1248 citations.
Papers
More filters
Journal ArticleDOI
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman,Igor Puzanov,Vivek Subbiah,Jason E. Faris,Ian Chau,Jean-Yves Blay,Juergen Wolf,Noopur Raje,Eli L. Diamond,Antoine Hollebecque,Radj Gervais,Maria Elena Elez-Fernandez,Antoine Italiano,Ralf-Dieter Hofheinz,Manuel Hidalgo,Emily Chan,Martin Schuler,Susan Frances Lasserre,Martina Makrutzki,Florin Sirzen,Maria Luisa Veronese,Josep Tabernero,José Baselga +22 more
TL;DR: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers and preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.
Journal ArticleDOI
VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).
Josep Tabernero,Emily Chan,José Baselga,Jean-Yves Blay,Ian Chau,David M. Hyman,Noopur Raje,Juergen Wolf,Florin Sirzen,Maria Luisa Veronese,Lada Mitchell,Manuel Hidalgo +11 more
TL;DR: Low prevalence of V600m in non-melanoma cancers requires novel trial designs to assess the activity of BRAF inhibitors, and based on preclinical models that V 600m positive (+) CRC upr...
Journal ArticleDOI
VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).
David M. Hyman,Jean-Yves Blay,Ian Chau,Noopur Raje,Maria Elena Elez Fernandez,Juergen Wolf,Florin Sirzen,Maria Luisa Veronese,Lada Mitchell,Igor Puzanov,José Baselga +10 more
TL;DR: Preliminary efficacy and safety data for the non-small cell lung cancer, cholangiocarcinoma (CLC), and Erdheim-Chester disease (ECD)/Langerhans cell histiocytosis (LCH) cohorts are presented.
Journal ArticleDOI
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
James Larkin,Paola Queirolo,Ana Arance,Michael P. Brown,Axel Hauschild,Michele Del Vecchio,Grant A. McArthur,Bart Neyns,Jürgen C. Becker,Johan Hansson,David W. Hogg,Paolo A. Ascierto,Carmen Loquai,Enrique Espinosa,Claus Garbe,Poulam M. Patel,Jacob Schachter,Lada Mitchell,Maria Luisa Veronese,Christian U. Blank +19 more
TL;DR: Preliminary safety and efficacy findings from a safety study of vemurafenib in pts with unresectable stage IIIC/IV mM with BRAFV600 mutations, associated with improved PFS and OS in patients with BRAfV600-mutant metastatic melanoma are presented.
Journal ArticleDOI
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma.
James Larkin,Michele Del Vecchio,Paolo A. Ascierto,Jacob Schachter,Claus Garbe,Bart Neyns,Mario Mandalà,Paul Lorigan,Wilson H. Miller,Alexander Guminski,Carola Berking,Piotr Rutkowski,Paola Queirolo,Axel Hauschild,Ana Arance,Michael P. Brown,Lada Mitchell,Maria Luisa Veronese,Christian U. Blank +18 more
TL;DR: Interim results from predefined subgroups from a large multicenter, open-label safety study of VEM in pts with mM, a BRAF kinase inhibitor, demonstrate high response rates and improved progression-free and overall survival in patients with BRAFV600mutation–positive metastatic melanoma.